Eduardo Dunayevich, MD

Neurocrine Biosciences, Inc., San Diego, California

  • 7Articles
  • 24.3KReads
  • 2000–2026Active
  • 42Collaborators
  • 136Citations

About

Eduardo Dunayevich, MD, is affiliated with Neurocrine Biosciences, Inc. in San Diego, California. His publications from 2000 to 2026 focus on clinical topics including schizophrenia and schizoaffective disorders, anxiety, bipolar disorder, tardive dyskinesia, and weight management. His work encompasses validation of patient-reported outcome measures, pharmacologic treatment studies, adverse event case reports, and metabolic risk factors associated with atypical antipsychotics. He has frequently collaborated with authors such as Mary Anne Dellva and Susan L. McElroy.

Publications

JCP
Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials
Narrative Review

Validation for the Tardive Dyskinesia Impact Scale, a Patient-Reported Outcome Measure in Valbenazine Clinical Trials

April 29, 2026

The TDIS followed a similar trajectory to other clinician- and patient-reported outcomes measured in tardive dyskinesia clinical trials, and a change of 4 points in total score is considered...
, , , et al
PCC
Article

Naltrexone/Bupropion Combination Therapy in Overweight or Obese Patients With Major Depressive Disorder: Results of a Pilot Study

June 20, 2013

In this study, 25 overweight or obese women with major depressive disorder received up to 24 weeks of open-label treatment with a combination of 32 mg per day of...
, , , et al
JCP
Original Research

Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation

February 9, 2010

, , , et al
JCP
Original Research

Longer Time to Antipsychotic Treatment Discontinuation for Any Cause Is Associated With Better Functional Outcomes for Patients With Schizophrenia, Schizophreniform Disorder, or Schizoaffective Disorder

August 15, 2007

, , , et al
PCC
Original Research

Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians

April 16, 2007

, , , et al
JCP
Letter to the Editor

Development of an Atherogenic Metabolic Risk Factor Profile Associated With the Use of Atypical Antipsychotics.

January 15, 2005

,
JCP
Original Research

Twelve-Month Outcome in Bipolar Patients With and Without Personality Disorders

July 31, 2000

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe